A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

Movement Disorders

Volumn 31, Issue 9, 2016, Pages 1373-1380

  Tison, François ^a,b,c,d   Keywood, Charlotte ^e   Wakefield, Mark ^e   Durif, Franck ^d,f   Corvol, Jean Christophe ^d,g   Eggert, Karla ^h   Lew, Mark ⁱ   Isaacson, Stuart ^j   Bezard, Erwan ^a,b   Poli, Sonia Maria ^e   Goetz, Christopher G ^k   Trenkwalder, Claudia ^l   Rascol, Olivier ^d,m  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d F CRIN   (France)

^e ADDEX PHARMACEUTICALS   (Switzerland)

^f SERVICE DE RHUMATOLOGIE   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h UNIVERSITY HOSPITAL MARBURG   (Germany)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j Parkinson's Disease and Movement Disorder Center of Boca Raton   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l Ctr Parkinsonism/Movement Disord   (Germany)

^m TOULOUSE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

dipraglurant; levodopa induced dyskinesia; mGluR5 antagonist; Parkinson's disease; phase 2A

Indexed keywords

DIPRAGLURANT; LEVODOPA;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ANXIETY; ARTICLE; ASTHENIA; CLINICAL EXAMINATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; ELIMINATION HALF-LIFE; FAINTNESS; FALLING; FATIGUE; FEMALE; HUMAN; HYPERTENSION; LEVODOPA-INDUCED DYSKINESIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; UNIFIED PARKINSON DISEASE RATING SCALE; VERTIGO; VISUAL HALLUCINATION; VISUAL IMPAIRMENT;

EID: 84985963089     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26659     Document Type: Article

References (9)

1. Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl 1):S179–188.
2. Péchevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956–963.
3. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2–S41.
4. Fisone G, Bezard E. Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol 2011;98:95–122.
5. Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014;20:947–956.
6. Bezard E, Pioli EY, Li Q, et al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord 2014;29:1074–1079.
7. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2014;28:1838–1846,
8. Goetz CG, Stebbins GT, Chung KA, et al. Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341–346.
9. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007;2:234–243.